CRESCO LABS’ DISPENSARY LAUNCHES NEWLY ENACTED ILLINOIS OPIOID ALTERNATIVE PILOT PROGRAM https://s3-us-west-2.amazonaws.com/maven-user-photos/theweedblog/medical/EY5AJpd_ekqbEzUORq8dTw/o1VGx7rOdEOqDs326Bt6TA Illinois alternative to opioid patient Tashena Altman makes first medical cannabis purchase under Illinois new law
Cresco Labs (CSE: CL) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced that the Company’s FloraMedex dispensary launched Illinois’ Opioid Alternative Pilot Program (OAPP) today vastly expanding the population of Illinois patients who can access medical cannabis in place of pharmaceutical opioid medications. Under this new program, patients with doctor approval can receive near-immediate access to cannabis products from an Illinois licensed dispensary. The OAPP eliminates the previously required red tape – fingerprinting and background checks – that often delay patients access to medical cannabis by up to three months. Under this act, Medical Cannabis Pilot Program (MCPP) patients with one of the 41 qualifying medical conditions designated by the state of Illinois, and a doctor recommendation can also receive a temporary medical cannabis card online and make immediate cannabis purchases without waiting for their permanent card to be processed.
Learn more here